Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
26 Feb 2024
26 Feb 2024
Historique:
received:
05
05
2023
accepted:
15
02
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
26
2
2024
Statut:
epublish
Résumé
This is a secondary data analysis of the TIPPING study, which included 1,121 patients with stage I-III breast cancer who had enumeration of CTCs (by either CellSearch or immunomagnetic enrichment and flow cytometry [IE/FC]) and disseminated tumor cells (DTCs) at the time of surgical resection between 1999 and 2012. The primary endpoint was mean number of CTCs by histology, taking into account method of detection and treatment type, and evaluation of histology specific prognostic cutpoints. Overall, patients with ILC had significantly higher CTC counts than those with IDC, a finding which persisted in the 382 patients with CTC enumeration by IE/FC method. Additionally, among those with primary surgery, patients with ILC had significantly higher mean CTC counts than those with IDC (mean 2.11 CTCs/mL versus 0.71 CTCs/mL respectively, p < 0.001), which persisted on multivariate analysis. Patients with ILC and CTC-high/DTC-high status trended towards reduced DRFS HR = 9.27, 95% CI 0.95-90.5, p = 0.055) and had significantly decreased BCSS (HR = 10.4, 95% CI 1.07-99.7, P = 0.043) compared with those who were CTC-low/DTC-low. In the IDC group, CTC-high/DTC-high status was not associated with either DRFS or BCSS. In neoadjvuantly treated patients, there was no significant difference in CTC counts in the ILC group versus the IDC group (mean 0.89 CTCs/mL versus 1.06 CTCs/mL respectively, p = 0.82). Our findings contribute to the limited literature on CTCs and DTCs in ILC, and suggest that clinical utility and optimal thresholds for CTC and DTC assays may differ by histologic subtype in early-stage breast cancer.
Identifiants
pubmed: 38409268
doi: 10.1038/s41523-024-00623-9
pii: 10.1038/s41523-024-00623-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : K08CA256047
Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Cristofanilli, M. et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit. Rev. Oncol. Hematol. 134, 39–45 (2019).
doi: 10.1016/j.critrevonc.2018.12.004
pubmed: 30771872
Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793–802 (2005).
doi: 10.1056/NEJMoa050434
pubmed: 16120859
Ismail, M. S. et al. Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin. Cancer Res. 10, 196–201 (2004).
doi: 10.1158/1078-0432.CCR-0515-2
pubmed: 14734470
Walter, V. P. et al. Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. Arch. Gynecol. Obstet. 297, 785–790 (2018).
doi: 10.1007/s00404-018-4669-9
pubmed: 29380106
Kasimir-Bauer, S. et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 18, 20 (2016).
doi: 10.1186/s13058-016-0679-3
pubmed: 26868521
pmcid: 4751719
Schindlbeck, C. et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J. Cancer Res. Clin. Oncol. 139, 1055–1062 (2013).
doi: 10.1007/s00432-013-1418-0
pubmed: 23525580
Hartkopf, A. D. et al. Simultaneous detection of disseminated and circulating tumor cells in primary breast cancer patients. Cancer Res. Treat. 48, 115–124 (2016).
doi: 10.4143/crt.2014.287
pubmed: 25687853
Molloy, T. J. et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 13, R61 (2011).
doi: 10.1186/bcr2898
pubmed: 21672237
pmcid: 3218950
Pierga, J.-Y. et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10, 1392–1400 (2004).
doi: 10.1158/1078-0432.CCR-0102-03
pubmed: 14977842
Kasimir-Bauer, S. et al. Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Sci. Rep. 6, 26355 (2016).
doi: 10.1038/srep26355
pubmed: 27212060
pmcid: 4876469
Liu, M. C. et al. First-line doublet chemotherapy for metastatic triple-negative breast cancer: circulating tumor cell analysis of the tnAcity trial. Cancer Manag. Res. 11, 10427–10433 (2019).
doi: 10.2147/CMAR.S208712
pubmed: 31849532
pmcid: 6913260
Hartkopf, A. D. et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur. J. Cancer 154, 128–137 (2021).
doi: 10.1016/j.ejca.2021.06.028
pubmed: 34265505
Volmer, L. et al. Neoadjuvant chemotherapy of patients with early breast cancer is associated with increased detection of disseminated tumor cells in the bone marrow. Cancers 14, https://www.mdpi.com/2072-6694/14/3/635 (2022).
Magbanua, M. J. M. et al. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clin. Cancer Res. 25, 5388–5397 (2019).
doi: 10.1158/1078-0432.CCR-18-3888
pubmed: 31142502
pmcid: 6726564
Narbe, U. et al. The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast—long-term prognostic significance. Cells 9, 1718 (2020).
doi: 10.3390/cells9071718
pubmed: 32709042
pmcid: 7407940
Wilson, N., Ironside, A., Diana, A. & Oikonomidou, O. Lobular breast cancer: a review. Front. Oncol. 10, 591399 (2020).
doi: 10.3389/fonc.2020.591399
pubmed: 33520704
Pramod, N. et al. Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist 26, e943–e953 (2021).
doi: 10.1002/onco.13734
pubmed: 33641217
pmcid: 8176983
Janni, W. J. et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin. Cancer Res. 22, 2583–2593 (2016).
doi: 10.1158/1078-0432.CCR-15-1603
pubmed: 26733614
Johnson, K., Sarma, D. & Hwang, E. S. Lobular breast cancer series: imaging. Breast Cancer Res 17, 94 (2015).
doi: 10.1186/s13058-015-0605-0
pubmed: 26163296
pmcid: 4499185
Zhou, M. et al. Correlation between circulating tumor cells and different molecular biological characteristics in breast cancer patients. Gland Surg. 11, 466–471 (2022).
doi: 10.21037/gs-22-43
pubmed: 35284300
pmcid: 8899420
Bidard, F.-C. et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J. Natl. Cancer Inst. 110, 560–567 (2018).
doi: 10.1093/jnci/djy018
pubmed: 29659933
Mouabbi, J. A. et al. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res. Treat. 193, 253–264 (2022).
doi: 10.1007/s10549-022-06572-w
pubmed: 35347549
Thery, L. et al. Circulating tumor cells in early breast cancer. JNCI Cancer Spectr. 3, kz026 (2019).
doi: 10.1093/jncics/pkz026
Addanki, S., Meas, S., Sarli, V. N., Singh, B. & Lucci, A. Applications of circulating tumor cells and circulating tumor DNA in precision oncology for breast cancers. Int. J. Mol. Sci. 23, https://www.mdpi.com/1422-0067/23/14/7843 (2022).
Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13, 920–928 (2007).
doi: 10.1158/1078-0432.CCR-06-1695
pubmed: 17289886